retatrutide phase 3 results october 2025 just delivered the first top-line for a triple agonist in obesity β and the findings from TRIUMPH-4 are strikingπ Lilly's triple agonist delivers up
Description
These assets target a fast-expanding market driven by rising obesity and type 2 diabetes rates
Over the past decade, several studies have demonstrated that gut microbial populations are closely associated with metabolic disorders such as dyslipidemia, obesity, and diabetes (175)
(GLP-1):
You do not want any artificial flavors on the ingredient label, Berghoff warns
If you like the accountability of a long-term contract
The practical guidance most clinicians give: don't overthink it
